In a recent interview with Bloomberg, 23andMe CEO Anne Wojcicki said the company was considering splitting its consumer and therapeutics businesses in an effort to boost its stock price and maintain its listing. From a report: Bloomberg noted that the stock has lost more than 90% of its value since the company went public in 2021 through a SPA ... ⌘ Read more
In a recent interview with Bloomberg, 23andMe CEO Anne Wojcicki said the company was considering splitting its consumer and therapeutics businesses in an effort to boost its stock price and maintain its listing. From a report: Bloomberg noted that the stock has lost more than 90% of its value since the company went public in 2021 through a SPA ... ⌘ Read more